Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine

Table 2

Responses to antiemetic therapy.

Response	Ondansetron; Arm 1; Number (%)	Ondansetron + aprepitant; Arm 2; Number (%)
Overall response	28 (67)	33 (80)	0.11
Complete response	20 (48)	21 (51)	0.45
Partial response	8 (19)	12 (29)	0.20
Failure	14 (33)	8 (19)	0.11